Resource

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.

Foley, J E; Bunck, M C; Möller-Goede, D L; Poelma, M; Nijpels, G; Eekhoff, E M; Schweizer, A; Heine, R J; Diamant, M
Diabetologia; 2011 Aug;54(8):1985-91. PMID: 21547496
Novartis Pharmaceutical Cooperation, Clinical Research and Development, One Health Plaza, East Hanover, NJ, 07936, USA, james.foley@novartis.com.
Category: 

Abstract

Traditional blood glucose lowering agents do not prevent the progressive loss of beta cell function in patients with type 2 diabetes. The dipeptidylpeptidase (DPP)-4 inhibitor vildagliptin improves beta cell function both acutely and chronically (up to 2 years). Whether this effect persists after cessation of treatment remains unknown. Here, we assessed the insulin secretory capacity in drug-naive patients with type 2 diabetes after a 52 week treatment period with vildagliptin or placebo, and again after a 12 week washout period.